140 related articles for article (PubMed ID: 34918596)
1. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement.
Guerini-Rocco E; Botti G; Foschini MP; Marchiò C; Mastropasqua MG; Perrone G; Roz E; Santinelli A; Sassi I; Galimberti V; Gianni L; Viale G
Tumori; 2022 Jun; 108(3):196-203. PubMed ID: 34918596
[TBL] [Abstract][Full Text] [Related]
2. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Bossuyt V
Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
[TBL] [Abstract][Full Text] [Related]
3. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients.
Bossuyt V; Spring L
Breast J; 2020 Jun; 26(6):1189-1198. PubMed ID: 32468652
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
Bossuyt V; Provenzano E; Symmans WF; Boughey JC; Coles C; Curigliano G; Dixon JM; Esserman LJ; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Viale G; Cameron D;
Ann Oncol; 2015 Jul; 26(7):1280-91. PubMed ID: 26019189
[TBL] [Abstract][Full Text] [Related]
5. Standardizing of Pathology in Patients Receiving Neoadjuvant Chemotherapy.
Bossuyt V; Symmans WF
Ann Surg Oncol; 2016 Oct; 23(10):3153-61. PubMed ID: 27380637
[TBL] [Abstract][Full Text] [Related]
6. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
[TBL] [Abstract][Full Text] [Related]
7. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting.
Sahoo S; Lester SC
Arch Pathol Lab Med; 2009 Apr; 133(4):633-42. PubMed ID: 19391665
[TBL] [Abstract][Full Text] [Related]
8. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: Current recommendations and challenges.
See SHC; Siziopikou KP
Pathol Res Pract; 2022 Feb; 230():153753. PubMed ID: 34990870
[TBL] [Abstract][Full Text] [Related]
9. [GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].
Maran-Gonzalez A; Franchet C; Duprez-Paumier R; Antoine M; Barlier C; Becette V; Berghian A; Blanc-Fournier C; Brabencova E; Charafe-Jauffret E; Chenard MP; Dauplat MM; Delrée P; Fleury C; Garbar C; Ghnassia JP; Haudebourg J; MacGrogan G; Mathieu MC; Michenet P; Penault-Llorca F; Poulet B; Robin Y; Roger P; Russ E; Treilleux I; Valent A; Verriele V; Vincent-Salomon A; Arnould L; Lacroix-Triki M;
Ann Pathol; 2019 Dec; 39(6):383-398. PubMed ID: 31257035
[TBL] [Abstract][Full Text] [Related]
10. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
Carey LA; Metzger R; Dees EC; Collichio F; Sartor CI; Ollila DW; Klauber-DeMore N; Halle J; Sawyer L; Moore DT; Graham ML
J Natl Cancer Inst; 2005 Aug; 97(15):1137-42. PubMed ID: 16077072
[TBL] [Abstract][Full Text] [Related]
11. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Campbell JI; Yau C; Krass P; Moore D; Carey LA; Au A; Chhieng D; Giri D; Livasy C; Mies C; Rabban J; Sarode VR; Singh B; Esserman L; Chen YY
Breast Cancer Res Treat; 2017 Aug; 165(1):181-191. PubMed ID: 28577078
[TBL] [Abstract][Full Text] [Related]
12. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
[TBL] [Abstract][Full Text] [Related]
13. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy.
Sahoo S; Krings G; Chen YY; Carter JM; Chen B; Guo H; Hibshoosh H; Reisenbichler E; Fan F; Wei S; Khazai L; Balassanian R; Klein ME; Shad S; Venters SJ; Borowsky AD; Symmans WF; Ocal IT
Arch Pathol Lab Med; 2022 May; 147(5):591-603. PubMed ID: 35976643
[TBL] [Abstract][Full Text] [Related]
14. Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
Pfob A; Cai L; Schneeweiss A; Rauch G; Thomas B; Schaefgen B; Kuemmel S; Reimer T; Hahn M; Thill M; Blohmer JU; Hackmann J; Malter W; Bekes I; Friedrichs K; Wojcinski S; Joos S; Paepke S; Degenhardt T; Rom J; Rody A; van Mackelenbergh M; Banys-Paluchowski M; Große R; Reinisch M; Karsten MM; Sidey-Gibbons C; Wallwiener M; Golatta M; Heil J
Ann Surg Oncol; 2024 Feb; 31(2):957-965. PubMed ID: 37947974
[TBL] [Abstract][Full Text] [Related]
15. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
Rabban JT; Glidden D; Kwan ML; Chen YY
Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Steenbruggen TG; van Seijen M; Janssen LM; van Ramshorst MS; van Werkhoven E; Vrancken Peeters MTDF; Wesseling J; Lips EH; Sonke GS
Clin Cancer Res; 2019 Aug; 25(16):4985-4992. PubMed ID: 31076546
[TBL] [Abstract][Full Text] [Related]
17. Characterization and clinical impact of residual disease after neoadjuvant chemotherapy.
Viale G
Breast; 2013 Aug; 22 Suppl 2():S88-91. PubMed ID: 24074800
[TBL] [Abstract][Full Text] [Related]
18. The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.
Burgués O; López-García MÁ; Pérez-Míes B; Santiago P; Vieites B; García JF; Peg V
Clin Transl Oncol; 2018 Mar; 20(3):382-391. PubMed ID: 28795336
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
Fontanella C; Loibl S; von Minckwitz G
Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
